Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema (GlobeNewswire) - Apr 20, 2026 - "The last patient in the DIAMOND (DIAbetic Macular edema patients ON a Drop) program, consisting of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52 weeks of treatment, completed the final study visit in April 2026....Oculis expects to report topline data from both pivotal trials in June, followed by a potential NDA submission in Q4 2026."
FDA filing • P3 data: top line • Trial status • Diabetic Macular Edema
|